Enfortumab vedotin is supplied under the trade name Padcev. It is a novel therapeutic drug approved by the FDA and has a positive role in the management of metastatic urothelial cancer. The clinical research outcomes suggest its significance in the treatment of recurrent bladder cancer and urothelial carcinoma. This therapeutic drug is developed by Astellas Pharma. Padcev (enfortumab vedotin) injection in India is a noted recommendation by the Medical Oncologists.
This innovative drug is available as 20 mg and 30 mg single-use vial lyophilized powder for solution for IV infusion only, at a dose of 1.25 mg/kg (up to a maximum of 125 mg for patients ≥ 100 kg) administered intravenously (IV) over a half-hour on days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
Padcev 20 mg/ 30 mg vials in India may be prescribed after due consultations with the patient. Its limited access is clearly because of the registration status in India, this medication is not formally registered. This should not completely limit India-based patients from procuring Padcev injections. Provisions like Named Patient Program (NPP) are available to import Padcev (enfortumab vedotin).
Searching Padcev (enfortumab vedotin) in India? We can help you:
If you are looking to import enfortumab vedotin in India, you can take our help to procure the medicine. Our experienced team will help you network with legitimate suppliers who can supply the medicine to India. We have a track record of assisting India-based patients with the necessary documentation and procedures. The sources or suppliers we connect you with are duly authorized/licensed to help facilitate Padcev (enfortumab vedotin) import in India.
We welcome your inquiries. Feel free to reach out to us through our TOLL-FREE helpline: 1800-889-1064 or connect with us via Call/WhatsApp: +91 9310090915.
References:
https://www.padcev.com/
https://www.ncbi.nlm.nih.gov/books/NBK595376/
